欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日韩人妻一区二区三区蜜 | 中文字幕无线码中文字幕网站 | 国产在线精品一区二区三区精品 | 午夜福利视| 成人国产欧美大片一区 | 国产亚洲精品精品国产亚洲综合 | 探花精品偷拍在线播放 | 黃色a片三級三級三級 | 国产精品成人99久久久久麻豆 | 国产精彩亚洲中文 | 岛国大片在线观看免费版 | 国产欧美在 | 国产情侣自拍小视频 | 欧洲日产国码二区 | 亚洲性爱乱伦无码视频网 | 男人添女人下部高潮全视频 | 日韩国产欧美一区二区三区 | 亚洲国产综合视频 | 欧美日韩中文在线视频 | 欧美一区二区三区成人片在线 | 久久这里一区二区精品 | 国产在线啊v观看不 | 精品国产亚洲一区二区三区 | 日韩精品一区二区三区免费在线 | 日韩精品一品道一区二区 | 亚洲αv久久久噜噜噜噜噜 亚洲а∨无码2025在线观看 | 伦子系列午睡沙发 | 亚洲精品自在在线观看 | 最近最新的免费中文字幕 | 制服丝袜人妻中文字幕在线 | 深夜福利久久精品酒店 | 亚洲精品第一页国产精品 | 国产精品自在线看无码 | 精品久久综合1区2区3区激情 | 成人看片 | 色综合视频一区 | 久久伊人一区二区 | 欧美无砖专区一中文字 | 精品福利视频一区二区 | 亚洲国产中文 | 91麻豆精品国产高清在线 |